National Research Center for Hematology, Russia

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders

Not yet recruiting

Conditions: Non-Hodgkin Lymphoma, B-cell
Acute Lymphoblastic Leukemia ALL

First Posted Date: 2024-12-06

Last Posted Date: 2024-12-06

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 60

Registration Number: NCT06721598

Locations: 🇷🇺
National Medical Research Center for Hematology, Moscow, Russian Federation

A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders

Phase 1

Recruiting

Conditions: Non-Hodgkin Lymphoma, B-cell
Acute Lymphoblastic Leukemia ALL

Interventions: Biological: Hem101

First Posted Date: 2024-11-26

Last Posted Date: 2024-12-03

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 60

Registration Number: NCT06705530

Locations: 🇷🇺
National Medical Research Center for Hematology, Moscow, Russian Federation

IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML

Phase 3

Recruiting

Conditions: Early Relapses of Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Other: Intensive therapy
Other: Low intensity therapy

First Posted Date: 2024-05-17

Last Posted Date: 2024-05-17

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 198

Registration Number: NCT06418776

Locations: 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation

MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

Not Applicable

Recruiting

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions: Drug: blinatumomab for B-ALL, venetoclax for T-ALL

First Posted Date: 2024-02-01

Last Posted Date: 2024-02-01

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 200

Registration Number: NCT06237192

Locations: 🇷🇺
Olga Aleshina, Moscow, Russian Federation

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Phase 3

Recruiting

Conditions: Primary Mediastinal Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide Phosphate
Drug: Prednisolone
Drug: Rituximab
Drug: Vincristine Sulfate
Drug: Filgrastim
Drug: Pegfilgrastim
Drug: Nivolumab 40 mg in 4 ml Injection

First Posted Date: 2024-01-03

Last Posted Date: 2024-01-03

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 100

Registration Number: NCT06188676

Locations: 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation

Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Phase 2

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: Nivolumab

First Posted Date: 2022-12-21

Last Posted Date: 2022-12-21

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 50

Registration Number: NCT05660993

Locations: 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation

RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL

Phase 2

Recruiting

Conditions: Primary CNS Lymphoma

Interventions: Drug: Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide

First Posted Date: 2022-06-21

Last Posted Date: 2022-06-21

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 30

Registration Number: NCT05425654

Locations: 🇷🇺
Nathional Medical Research Center for Hematology, Moscow, Russian Federation

The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

Not Applicable

Recruiting

Conditions: AML

Interventions: Procedure: allo-HSCT

First Posted Date: 2022-04-21

Last Posted Date: 2022-04-21

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 75

Registration Number: NCT05339204

Locations: 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation

Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccination

Completed

Conditions: SARS-CoV-2 Vaccination
SARS-CoV-2 Infection

Interventions: Diagnostic Test: Corona-T-test

First Posted Date: 2021-12-21

Last Posted Date: 2021-12-21

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 220

Registration Number: NCT05165719

Locations: 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation

Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis

Phase 3

Not yet recruiting

Conditions: Cyclophosphamide Adverse Reaction
Graft Versus Host Disease
Hematologic Malignancy

Interventions: Drug: Post-transplantation Cyclophosphamide at dose 50 mg/kg/day
Drug: Post-transplantation Cyclophosphamide at dose 25 mg/kg/day

First Posted Date: 2021-12-15

Last Posted Date: 2022-01-11

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 100

Registration Number: NCT05158608

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy